RAF1 as a standalone therapeutic target in KRAS-driven lung adenocarcinoma: No added efficacy from co-targeting ARAF, EGFR, or DDR1.

KRAS-mutant lung adenocarcinoma remains without effective targeted therapies for most patients, particularly those with non-G12C alleles or resistance to KRASG12C inhibitors. RAF1 is essential for KRAS-driven tumor maintenance through kinase-independent survival functions, making it an attractive ca...

Descripción completa

Detalles Bibliográficos
Autores: de-la-Puente-Ovejero, Laura, Fernández-Rodríguez, Ana, Francoz, Sarah, Aizpurua, Gonzalo, Lomba-Riego, Lucía, Drosten, Matthias, Guerra, Carmen, Musteanu, Mónica, Barbacid, Mariano, García-Alonso, Sara
Tipo de recurso: artículo
Fecha de publicación:2026
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:dnet:repisalud__::a3776a84b1e4f18ec66c8018666f660f
Acceso en línea:https://hdl.handle.net/20.500.12105/27498
Access Level:acceso abierto
Palabra clave:K-RAS ONCOGENE
A-RAF
B-RAF
PROTEIN-KINASE
APOPTOSIS
MICE
REGRESSION
MUTATIONS
LETHALITY
Descripción
Sumario:KRAS-mutant lung adenocarcinoma remains without effective targeted therapies for most patients, particularly those with non-G12C alleles or resistance to KRASG12C inhibitors. RAF1 is essential for KRAS-driven tumor maintenance through kinase-independent survival functions, making it an attractive candidate for targeted protein degradation. However, the therapeutic impact and safety of co-targeting RAF1 with related kinases remain unclear.

Similares en LA Referencia